Grow-Through and Penetration of the 0.2/0.22 "Sterilizing" Membranes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Grow-Through and Penetration of the 0.2/0.22 "Sterilizing" Membranes


Pharmaceutical Technology




In the 1960s, researchers discovered that organisms retained on the upstream side of a microporous membrane could penetrate it after a period of time and appear on the downside. Investigations showed this occurred both when the liquid flow was ongoing, as in dynamic aqueous systems, and during static periods, when there was no flow, but the filter was still in place in a wet condition. Not all organisms exhibited this action, nor was the time interval the same for those that did.

Although grow-through was still a present concern, its imminence was assuaged by the US Food and Drug Administration. In 1976, in its proposed good manufacturing practices (GMPs) for large-volume parenterals (LVPs), FDA addressed the problem by requiring that the mixing and filtration of a batch be completed within the eight-hour period of a single shift, an interval too brief for grow-through to occur (1). Although this proposal was never finalized, in the actual event it became the rule. (Indeed, its application discouraged the long-term use of membrane filters at points-of-use in water systems before the validation of sanitizing practices enabled its management.)

Wallhäusser described a companion phenomenon, "blow-through," as resulting from the imposition of pressure upon a wet membrane within whose pores organisms had already partly grown or penetrated (2). For example, instead of a "normal" release of 1 or 2 bacteria per liter through a membrane, 29 penetrated after an overnight shutdown and restart under pressure the next day. Following a flush of some liters, the bacterial passage declined to a "normal" number.

The grow-through phenomenon was rationalized as being a result of a binary fission whereby an organism cell divides into two during its reproduction. Presumably, in this reduced cell size, the organism can penetrate an otherwise impermeable membrane (3, 4).

Another explanation recognized the existence of pore-size distributions in membranes. Researchers postulated that the continuing growth of organisms on the wet membrane eventually yields numbers sufficient to encounter even the occasional large pore, thereby leading to penetration. (Interestingly, this explanation was strongly advanced by a filter manufacturer who had the good fortune to recognize the potential shortcoming in competitive filters that he asserted was absent from his.)

The grow-through experience proved difficult to investigate because not all organisms showed the effect, and those that did differed in their response times. The total contact time between the organism and the drug is seldom known, as also whether the same organism types have been involved in each of the exposures, and whether under roughly the same conditions such as temperature. Indeed, some investigators dispute the "grow-through" and "blow-through" episodes. Carter and Levy discuss that view, stating, "Both phenomena are hypotheses and have never been rigorously demonstrated to be real events in pharmaceutical processes" (5). There is the belief that such events, culminating in organism passage through 0.2/0.22 μm-rated membranes, are overstated as they pertain to pharmaceutical processing contexts.

Grow-through versus reverse osmosis membranes

Curiously, organisms may, on occasion, be found on the downside of reverse osmosis (RO) membranes, although these have smaller "pores" than 0.1 μm-rated membranes and would seem far less likely to permit grow-through. Unlike the case of microporous membranes, the integrity testing of RO membranes does not involve correlations with organism retentions. It is, therefore, possible that "imperfect" RO membranes rather than grow-through is the cause of such occurrences. Carter hypothesized the presence of pinholes in RO filters (6).

Manufacturing techniques have undoubtedly improved since 1976. Nonetheless, the intersegmental spaces among the convoluted polymer molecules that constitute the pores of the RO membranes are exceedingly small. Their castings are, therefore, much more liable to be compromised by the incorporation of miniscule particle-inclusions that are not significant in microporous membranes. Tellingly, perhaps, RO membranes are not relied upon to produce sterile effluent. Indeed, FDA is generally regarded as being wary even of the use of two-pass, product-staged RO, at least for the production of water for injection.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here